180 Life Sciences Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of 180 Life Sciences Corp. generated cash of -$10,922,223, which is more than the previous year. Cash used in financing activities reached the amount of $5,907,887 last year. Net change in cash is therefore -$4,994,311.
Cash Flow
| 2017 | -497.35K | -115.92M | 116.78M |
|---|---|---|---|
| 2018 | -3.91K | -90 | 4.76K |
| 2019 | -3.31M | -708.14K | 3.94M |
| 2020 | -3.87M | 14.49M | -8.73M |
| 2021 | -19.37M | 0 | 25.41M |
| 2022 | -12.12M | 0 | 10.87M |
| 2023 | -10.92M | 0 | 5.90M |
ATNF Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.97M | 8.22M | 2.10M | 83.39K | 567.22K | 428.39K | 67.25K |
Operating activities | |||||||
Net income | -19.93M | -38.72M | -20.32M | -10.88M | -25.39M | -14.49K | 123.76K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 105.67K | 109.00K | 109.94K | 125.33K | 72.24K | 23 | 0 |
Stock-based compensation expense | 2.28M | 2.96M | 5.00M | 1.11M | 13.29M | 0 | 0 |
| Deferred income tax benefit | 2.28M | 2.96M | 5.00M | 1.11M | 13.29M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 286.41K | 1.21M | -5.73M | 2.22M | 2.89M | 70.17K | -53.56K |
Cash generated by operating activities | -10.92M | -12.12M | -19.37M | -3.87M | -3.31M | -3.91K | -497.35K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 3 | 0 | 0 | 0 | -144.40K | -30 | 0 |
Acquisitions Net | 0 | 0 | 0 | 3.00M | 86.07K | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 14.49M | -708.14K | -90 | -115.92M |
Financing activities | |||||||
Common Stock Issued | 5.99M | 12.49M | 26.66M | 72.5K | 1.13M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -1.01M | 0 | -9.00M | 0 | 0 | 0 |
Repayments of term debt | -288.06K | -530.14K | -817.59K | -72.84K | 2.68M | 0 | 0 |
Cash used in financing activities | 5.90M | 10.87M | 25.41M | -8.73M | 3.94M | 4.76K | 116.78M |
Net Change In Cash | -4.99M | -1.25M | 6.11M | 2.02M | -483.82K | -157.50K | 361.14K |
Cash at end of period | 1.97M | 6.97M | 8.22M | 2.10M | 83.39K | 270.88K | 428.39K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |